申联生物(688098) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was CNY 358,429,248.99, representing a 6.13% increase compared to CNY 337,732,400.53 in 2020[23]. - Net profit attributable to shareholders of the listed company decreased by 14.91% to CNY 110,201,862.80 from CNY 129,514,301.93 in the previous year[23]. - The net cash flow from operating activities was CNY 90,119,983.59, down 19.34% from CNY 111,730,338.42 in 2020[23]. - The company's total assets increased by 5.55% to CNY 1,598,464,318.21 at the end of 2021, compared to CNY 1,514,469,447.73 at the end of 2020[23]. - Basic earnings per share decreased by 15.63% to CNY 0.27 in 2021 from CNY 0.32 in 2020[24]. - The gross margin for the main business was 75.69%, down 7.98 percentage points from the previous year[110]. - The company achieved operating revenue of CNY 358.43 million, a year-on-year increase of 6.13%, with the main business revenue being CNY 357.79 million, up 6.05% from the previous year[105]. - Operating costs increased by 57.89% compared to the previous year, primarily due to the formal production and sales of the "Porcine Foot-and-Mouth Disease O-type and A-type Bivalent Inactivated Vaccine," leading to higher depreciation of fixed assets[107]. - The net profit attributable to shareholders was CNY 110.20 million, a decrease of 14.91% year-on-year[104]. - The net cash flow from investment activities worsened by 41.19%, from -90,099,196.87 to -127,210,857.42 RMB[119]. Research and Development - Research and development expenses accounted for 19.14% of operating revenue, an increase of 9.13 percentage points from 10.01% in 2020[24]. - Total R&D investment increased significantly to CNY 68,585,557.93, a 102.94% increase compared to the previous year[69]. - The company has increased its R&D output, with a total of 92 patent applications and 77 granted patents, reflecting its commitment to innovation[68]. - The company has established four major technology platforms, including synthetic peptide vaccine technology and inactivated vaccine technology, enhancing its competitive edge in the industry[78]. - The company is focusing on developing a competitive intellectual property system related to virus-like particle vaccine technology, with multiple proprietary technologies achieved[128]. - The company plans to increase R&D efforts for multivalent and multi-component vaccines to reduce the number of vaccinations required for livestock, addressing new demands in vaccine development[59]. - The company has made significant progress in developing a range of vaccines for swine diseases, including the recombinant foot-and-mouth disease vaccine and the three-in-one inactivated vaccine for swine infectious diseases[130]. Product Development and Innovation - The company successfully launched the new product "Tai Ji Lian," which won the "2021 Annual Influential Foot-and-Mouth Disease Vaccine" award in China[34]. - The company obtained new veterinary drug registration certificates for the bovine foot-and-mouth disease bivalent synthetic peptide vaccine and the porcine circovirus type 2 subunit vaccine[35]. - The company has developed the first domestic bivalent synthetic peptide vaccine for foot-and-mouth disease (FMD) in pigs, consisting of peptides 2700+2800+MM13[60]. - The company has successfully developed a bivalent inactivated vaccine for foot-and-mouth disease, which has received a first-class new veterinary drug registration certificate and is recognized for its high immunogenicity and protection[83]. - The company is actively developing other inactivated vaccines, including a subunit vaccine for porcine circovirus type 2, which is currently in trial production[65]. - The company has completed trial production of diagnostic kits for African swine fever and FMD, with ongoing efforts to obtain product approval numbers[67]. Market Position and Strategy - The company ranked fifth in the domestic pig biological products market with a sales amount of 338 million yuan in 2020, representing a market share of 4.88%[53]. - The company is actively expanding its product line, with ongoing projects for vaccines against porcine infectious gastroenteritis and porcine epidemic diarrhea[35]. - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[106]. - The company aims to focus on high-end markets and develop vaccines for major diseases affecting livestock, including foot-and-mouth disease and African swine fever[154]. - The company plans to launch a bivalent inactivated vaccine for foot-and-mouth disease, adjusting sales strategies to prioritize market sales over government procurement[155]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Dahua Certified Public Accountants, ensuring the accuracy of its financial statements[6]. - The company’s board of directors and management have confirmed the authenticity and completeness of the annual report, ensuring transparency[6]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties, ensuring financial integrity[8]. - The company has not violated decision-making procedures for external guarantees, maintaining compliance with regulations[8]. - The company emphasizes the importance of risk factors in its future operations, urging investors to carefully consider potential risks[7]. - The company strictly adheres to corporate governance regulations, ensuring the protection of shareholder rights and the effective operation of its governance structure[163]. Talent Development and Human Resources - The company has established a comprehensive talent development and incentive system to enhance team capabilities and cohesion[38]. - The R&D team consists of 69 members, accounting for 23.23% of the total workforce, with expertise in various fields such as biological engineering and veterinary medicine[88]. - The company aims to optimize its compensation incentive system to enhance employee motivation and creativity, conducting external salary surveys to ensure competitiveness[197]. - The company established the Shunlian Training Center in June 2021 to focus on employee growth and development, offering systematic learning environments[198]. Future Outlook and Guidance - The company provided guidance for the next fiscal year, projecting revenue growth of 25% to $625 million[174]. - The company plans to increase its marketing budget by 30% to support new product launches and market expansion efforts[176]. - Overall, the company remains optimistic about future growth, driven by strong user engagement and innovative product offerings[174].